MedPage Today on MSN
PAM Inhibitor Doubles Time to Progression in Advanced Breast Cancer Subset
Novel gedatolisib is currently under review at FDA for wild-type patients ...
A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib ...
Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer ...
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
Gedatolisib is a PAM pathway inhibitor – combining PI3K and mTOR inhibition in one molecule – and in the VIKTORIA-1 trial was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results